- Home
- ANAB vs NEXN Comparison
ANAB vs NEXN Comparison
Compare ANAB & NEXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- NEXN
- Stock Information
- Founded
- ANAB 2005
- NEXN 2007
- Country
- ANAB United States
- NEXN Israel
- Employees
- ANAB N/A
- NEXN N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- NEXN Computer Software: Programming Data Processing
- Sector
- ANAB Health Care
- NEXN Technology
- Exchange
- ANAB Nasdaq
- NEXN Nasdaq
- Market Cap
- ANAB 621.1M
- NEXN 669.0M
- IPO Year
- ANAB 2017
- NEXN 2021
- Fundamental
- Price
- ANAB $26.94
- NEXN $11.01
- Analyst Decision
- ANAB Buy
- NEXN Strong Buy
- Analyst Count
- ANAB 10
- NEXN 9
- Target Price
- ANAB $49.00
- NEXN $13.50
- AVG Volume (30 Days)
- ANAB 526.3K
- NEXN 799.8K
- Earning Date
- ANAB 08-08-2025
- NEXN 08-21-2025
- Dividend Yield
- ANAB N/A
- NEXN N/A
- EPS Growth
- ANAB N/A
- NEXN N/A
- EPS
- ANAB N/A
- NEXN 0.65
- Revenue
- ANAB $111,872,000.00
- NEXN $369,375,000.00
- Revenue This Year
- ANAB N/A
- NEXN $5.43
- Revenue Next Year
- ANAB $24.39
- NEXN N/A
- P/E Ratio
- ANAB N/A
- NEXN $17.02
- Revenue Growth
- ANAB 387.20
- NEXN 10.36
- 52 Week Low
- ANAB $12.21
- NEXN $6.34
- 52 Week High
- ANAB $41.31
- NEXN $12.60
- Technical
- Relative Strength Index (RSI)
- ANAB 66.30
- NEXN 59.75
- Support Level
- ANAB $25.48
- NEXN $9.73
- Resistance Level
- ANAB $28.50
- NEXN $11.59
- Average True Range (ATR)
- ANAB 1.26
- NEXN 0.43
- MACD
- ANAB 0.02
- NEXN 0.15
- Stochastic Oscillator
- ANAB 70.23
- NEXN 72.25
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.